Drinabant

Drinabant (also known by its research code AVE1625) is a cannabinoid receptor antagonist that was developed for the treatment of various medical conditions, including obesity and smoking cessation. It is a member of the class of drugs known as cannabinoid receptor antagonists, which work by blocking the action of endocannabinoids on the CB1 receptors in the brain.

Mechanism of Action

Drinabant functions by selectively inhibiting the CB1 receptors, which are primarily located in the central nervous system and peripheral nervous system. By blocking these receptors, Drinabant reduces the effects of endocannabinoids, which are involved in regulating appetite, mood, and other physiological processes.

Development and Clinical Trials

Drinabant was developed by the pharmaceutical company Sanofi. It underwent several phases of clinical trials to evaluate its efficacy and safety in treating conditions such as obesity and smoking cessation. However, the development of Drinabant was eventually discontinued due to concerns about its safety profile, particularly its association with adverse psychiatric effects.

Potential Uses

Despite its discontinuation, Drinabant was initially investigated for several potential therapeutic uses:

• Obesity: By blocking the CB1 receptors, Drinabant was thought to reduce appetite and promote weight loss.
• Smoking cessation: Drinabant was also studied for its potential to help individuals quit smoking by reducing the rewarding effects of nicotine.

Adverse Effects

During clinical trials, Drinabant was associated with several adverse effects, including:

• Depression
• Anxiety
• Nausea
• Dizziness

These adverse effects were significant enough to halt further development of the drug.

Related Compounds

Drinabant is part of a broader class of cannabinoid receptor antagonists, which includes other compounds such as:

• Rimonabant
• Taranabant

See Also

• Cannabinoid receptor
• Endocannabinoid system
• Obesity
• Smoking cessation